← Eichor
Study identifier: NCT06440915 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children

Condition: Aspergillosis Invasive · Mucormycosis  ·  Sponsor: Shanghai Children's Medical Center

PhaseNA
Planned participants200
Who can joinAll sexes, N/A to 18 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn the plasma concentration of isavuconazole in pediatric patients. It will also learn about the relationship of isavuconazole plasma concentrations to efficacy and safety in pediatric patients. The main questions it aims to answer are: What is the plasma concentration after using isavuconazole in pediatric patients? What is the effective range of plasma concentration of isavuconazole in pediatric patients? What is the safe range of plasma concentration of isavuconazole in pediatric patients? Researchers will measure the plasma concentration of isavuconazole to see whether it is appropriate. Participants will: Take drug isavuconazole as prescribed by the doctor; 1mL of blood is drawn 30min before the next dose.

This description comes directly from the study's public registry record.

Talk to the study team

Juan Wu, PhD  ·  +8618918397709  ·  wujuan@scmc.com.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Children's Medical CenterShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06440915